指南与共识主动脉疾病

女性非指南合规EVAR与死亡和再干预增加相关

Non-guideline-compliant endovascular abdominal aortic aneurysm repair in women is associated with increased mortality and reintervention compared with men.
指南 / 共识 · J Vasc Surg · 2021-07-22

基于SVS血管质量倡议2015-2019年25112例择期EVAR分析,非指南合规EVAR占38.5%,男性更常接受此类手术(90% vs 10%)。但女性非合规EVAR后30天死亡率(1.8% vs 0.5%)、并发症及1年再干预率(11.5% vs 5.8%)均显著高于男性。

要点

  • 女性非指南合规EVAR后30天死亡率1.8%,显著高于男性0.5%。
  • 女性非合规EVAR后多种并发症及1年再干预率均显著增加。
  • 尽管男性更常接受非合规EVAR,女性短期不良结局更重。

核心结论

  • 女性接受非指南合规EVAR后短期并发症、30天死亡率和再干预率均高于男性。

研究设计与样本

  • 回顾性分析SVS血管质量倡议2015-2019年25112例择期EVAR(无合并髂动脉瘤≥3.0 cm)。
  • 非合规定义为男性<5.5 cm、女性<5.0 cm。

主要发现

  • 非合规EVAR共9675例(38.5%),男性占90%、女性占10%(OR 3.1,95%CI 2.9-3.4,P<.0001)。
  • 女性30天死亡率1.8% vs 男性0.5%(P=.0003)。
  • 女性并发症更高:心梗1% vs 0.3%(P=.006)、呼吸衰竭1.4% vs 0.6%(P=.01)、肠缺血0.7% vs 0.2%(P=.003)、入路血管血肿3% vs 1.2%(P=.0006)、髂入路血管损伤2.4% vs 0.8%(P<.0001)。
  • 女性1年再干预率11.5% vs 5.8%(P<.0001)。
  • 校正后女性30天死亡OR 3.1(95%CI 1.6-5.8,P=.0005)、院内并发症OR 1.9(95%CI 1.4-2.6,P<.0001)、再干预OR 1.5(95%CI 1.1-2.2,P=.02)。

关键数值与推荐

  • SVS指南合规EVAR直径阈值:男性≥5.5 cm,女性≥5.0 cm。

临床怎么用

  • 对女性应避免非指南合规EVAR,需严格遵循SVS直径阈值。
  • 临床决策时应充分评估女性非合规EVAR的高死亡和再干预风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sex-based disparities in surgical outcomes have emerged as an important focus in contemporary healthcare delivery. Likewise, the appropriate usage of endovascular abdominal aortic aneurysm repair (EVAR) in the United States remains a subject of ongoing controversy, with a significant number of U.S. EVARs failing to adhere to the Society for Vascular Surgery (SVS) clinical practice guideline (CPG) diameter thresholds. The purpose of the present study was to determine the effect of sex among patients undergoing EVAR that was not compliant with the SVS CPGs. METHODS: All elective EVAR procedures for abdominal aortic aneurysms without a concomitant iliac aneurysm (≥3.0 cm) in the SVS Vascular Quality Initiative were analyzed (2015-2019; n = 25,112). SVS CPG noncompliant repairs were defined as a size of <5.5 cm for men and <5.0 cm for women. The primary endpoint was 30-day mortality. The secondary endpoints were all-cause mortality, complications, and reintervention. Logistic regression was performed to control for surgeon- and patient-level factors. Freedom from the endpoints was determined using the Kaplan-Meier method. RESULTS: Noncompliant EVAR was performed in 9675 patients (38.5%). Although men were significantly more likely to undergo such procedures (90% vs 10%; odds ratio [OR], 3.1; 95% confidence interval [CI], 2.9-3.4; P < .0001), the 30-day mortality was greater for the women than the men (1.8% vs 0.5%; P = .0003). Women also experienced significantly higher rates of multiple complications, including postoperative myocardial infarction (1% vs 0.3%; P = .006), respiratory failure (1.4% vs 0.6%; P = .01), intestinal ischemia (0.7% vs 0.2%; P = .003), access vessel hematoma (3% vs 1.2%; P = .0006), and iliac access vessel injury (2.4% vs 0.8%; P < .0001). Additionally, women experienced increased overall 1-year reintervention rates (11.5% vs 5.8%; P < .0001). In the adjusted analysis, 30-day mortality and any in-hospital complication risk remained significantly greater for the women (30-day death: OR, 3.1; 95% CI, 1.6-5.8; P = .0005; in-hospital complication: OR, 1.9; 95% CI, 1.4-2.6; P < .0001). Women also experienced increased reintervention rates over time compared with men (OR, 1.5; 95% CI, 1.1-2.2; P = .02). CONCLUSIONS: Although men were more likely to undergo non-CPG compliant EVAR, women experienced increased short-term morbidity and 30-day mortality and higher rates of reintervention when undergoing non-CPG compliant EVAR. These unanticipated findings necessitate increased scrutiny of current U.S. sex-based EVAR practice and should caution against the use of non-CPG compliant EVAR for women.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ilyas S, Stone DH, Kang J, et al. Non-guideline-compliant endovascular abdominal aortic aneurysm repair in women is associated with increased mortality and reintervention compared with men. J Vasc Surg. 2021. PMID: 34302934. doi:10.1016/j.jvs.2021.07.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。